| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VSTM2A |
| Uniprot No | Q8TAG5-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-243aa |
| 氨基酸序列 | SQAKFTEFPRNVTATEGQNVEMSCAFQSGSASVYLEIQWWFLRGPEDLDP GAEGAGAQVKLLPDRDPDSDGTKISTVKVQGNDISHKLQISKVRKKDEGL YECRVTDANYGELQEHKAQAYLKVNANSHARRMQAFEASPMWLQDMKPRK NVSAAIPSSIHGSANQRTHSTSSPQVVAKIPKQSPQSGMETHFEPFILPL TNAPQKGQSYRVDRFMNGDFVDHHHHHH |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VSTM2A重组蛋白的3篇代表性文献示例(注：文献为虚构示例，仅作参考模板)：
1. **文献名称**：*"Recombinant VSTM2A Protein Inhibits Adipogenesis via Regulation of Wnt Signaling"*
**作者**：Li et al.
**摘要**：本研究通过大肠杆菌系统成功表达并纯化了重组VSTM2A蛋白，发现其能够通过调控Wnt/β-catenin通路抑制前脂肪细胞分化，提示其在代谢性疾病中的潜在治疗价值。
2. **文献名称**：*"Structural Characterization of VSTM2A and Its Interaction with Immune Receptors"*
**作者**：Smith et al.
**摘要**：利用X射线晶体学解析了VSTM2A重组蛋白的三维结构，并发现其胞外结构域可与T细胞表面受体CD6结合，为探索其在自身免疫疾病中的作用提供了分子基础。
3. **文献名称**：*"VSTM2A Recombinant Protein Attenuates Colorectal Cancer Progression by Modulating the Tumor Microenvironment"*
**作者**：Wang et al.
**摘要**：实验表明，重组VSTM2A蛋白通过抑制肿瘤相关巨噬细胞的M2极化，显著减少结直肠癌小鼠模型的肿瘤生长和转移，揭示了其作为免疫治疗靶点的潜力。
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“VSTM2A recombinant protein”获取最新研究。
VSTM2A (V-set and transmembrane domain-containing protein 2A) is a relatively understudied protein belonging to the immunoglobulin superfamily (IgSF), characterized by its extracellular V-set immunoglobulin-like domain and a single transmembrane helix. Initially identified through genomic analyses, it is encoded in humans by the *VSTM2A* gene located on chromosome 7 (7q31.32). Though its precise physiological role remains unclear, emerging evidence suggests involvement in immune regulation and metabolic processes. Structural homology to immune checkpoint molecules like B7 family proteins implies potential roles in modulating T-cell activity or inflammatory responses. Interestingly, VSTM2A has been linked to adipocyte biology, with studies showing upregulated expression during adipocyte differentiation and correlations with obesity-related metabolic disorders.
Recombinant VSTM2A protein is engineered for in vitro and in vivo studies to elucidate its functions. Typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, the purified protein retains its native conformation for ligand-receptor interaction assays. Researchers employ it to investigate signaling pathways, receptor binding partners (e.g., putative interactions with CD28 family receptors), and its dual context-dependent roles in diseases. In cancer biology, VSTM2A shows paradoxical expression patterns, acting as a tumor suppressor in some contexts while promoting metastasis in others. Its recombinant form also aids in developing diagnostic tools or therapeutic antibodies targeting metabolic-immune crosstalk. Quality validation often includes SDS-PAGE, Western blotting, and functional assays confirming bioactivity in cell-based models. Current research gaps include clarifying its endogenous ligands, downstream signaling mechanisms, and therapeutic potential in immuno-metabolic diseases.
×
